SCHEMBL629639

SCHEMBL629639

CN(C)C(=O)c1c(O)cccc1OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.56
BRD4 O60885 2/20 0.49
FOLH1 Q04609 1/20 0.49
MAPT P10636 2/20 0.49
MAPK1 P28482 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
EGFR P00533 2/20 0.46
HTR1A P08908 1/20 0.46
ADRA1D P25100 1/20 0.46
ADRA1A P35348 1/20 0.46
ADRA1B P35368 1/20 0.46
LIPE Q05469 1/20 0.45
PTGER1 P34995 1/20 0.45
SRC P12931 1/20 0.44
APP P05067 1/20 0.44
EDNRA P25101 1/20 0.44
MCL1 Q07820 1/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1728168 0.84 MAOB (0.76) MAOBBRD4FOLH1MAPTMAPK1
SCHEMBL30892463 0.84 MAOB (0.76) MAOBBRD4FOLH1MAPTMAPK1
SCHEMBL19336446 0.83 FOLH1 (0.62) MAOBFOLH1MAPTMAPK1TDP1
SCHEMBL5120937 0.81 CA12 (0.59) MAOBBRD4FOLH1MAPTMAPK1
SCHEMBL6358665 0.81 MAOB (0.56) MAOBBRD4FOLH1MAPTMAPK1
SCHEMBL3916276 0.80 BRD4 (0.45) BRD4FOLH1MAPTMAPK1TDP1
SCHEMBL7320619 0.80 NFKB1 (0.50) MAOBFOLH1MAPTMAPK1TDP1
SCHEMBL629367 0.79 KDM4E (0.47) BRD4FOLH1MAPTMAPK1TDP1
SCHEMBL12726937 0.79 TRPM8 (0.58) BRD4MAPTL3MBTL1PTGER1MEN1
SCHEMBL8323146 0.79 CA12 (0.64) MAOBFOLH1MAPTMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963292-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-02-22 EP disclosed
US-7700633-B2 Organic compounds NOVARTIS AG (CH) 2010-04-20 US disclosed
US-20080262050-A1 Organic Compounds NOVARTIS AG (CH) 2008-10-23 US disclosed
EP-1963292-A2 ORGANIC COMPOUNDS Novartis Pharma AG (CH) 2008-09-03 EP disclosed
WO-2007067615-A2 THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262050-A1 Organic Compounds PTPRS, PTPRO, PTPRC MAOB 1091/4885BRD4 3125/4885FOLH1 2829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.